期刊文献+

EphB-2受体及HER-2与EGFR在结直肠癌中的表达与意义 被引量:1

Expression and significance of EphB-2 receptor,HER-2 and EGFR in colorectal cancer
下载PDF
导出
摘要 目的探讨EphB-2受体、HER-2、EGFR的表达与结直肠癌生物学行为的关系。方法采用免疫组化染色检测86例结直肠癌组织标本中EphB-2受体、HER-2、EGFR的表达水平,以结直肠腺瘤组织标本47例作为对照。结果在癌旁无瘤黏膜、结直肠腺瘤和结直肠癌3组中,EphB-2受体的表达阳性率分别为100%(86/86)、95.7%(45/47)和83.7%(72/86);HER-2表达阳性率分别为34.9%(30/86)、42.6%%(20/47)和74.4%(64/86);EGFR表达阳性率分别为39.5%(34/86)、46.8%(22/47)和65.1%(56/86),癌旁无瘤黏膜、结直肠腺瘤与结直肠癌阳性率比较差异具有统计学意义(P<0.05)。在结直肠癌中EphB-2受体的表达与结直肠癌的分化程度、浸润深度、淋巴结转移有关,而HER-2、EGFR的表达与结直肠癌的浸润深度、淋巴结转移有关。结论 EphB-2受体、HER-2、EGFR对结直肠癌生物学行为有明显影响,可作为临床判断结直肠癌的生物学行为及预后的重要参考指标。 Objective To study the correlation between the biological behavior of colorectal carcinoma and the expression of EphB-2 receptor,HER-2 and EGFR.Methods The expression levels of EphB-2 receptor,HER-2 and EGFR in 86 cases of colorectal carcinoma were examined by immunohistochemical staining.Other 47 cases of colorectal adenoma samples were taken as controls.Results Compared with the normal mucosa or adenoma,the positive rate of EphB-2 receptor expressed in colorectal carcinoma significantly reduced from 100%(86/86)or 95.7%(45/47)to 83.7%(72/86),HER-2 expression significantly increased from 34.9%(30/86)or 42.6%(20/47)to 74.4%(64/86),and EGFR expression significantly increased from 39.5%(34/86)or 46.8%(22/47)to 65.1%(56/86).The positive rates of the normal mucosa and colorectal adenoma had statistically significant differences with colorectal cancer(P0.05).In colorectal cancer,the expression of EphB-2 receptor was related to its invasion depth,histological grade and lymph node metastasis,while the expression of HER-2 and EGFR was related to the invasion depth and lymph node metastasis.Conclusion EphB-2 receptor,HER-2 and EGFR can obviously affect the biological behavior of colorectal cancer.They may be important indexes to predict the biological behavior and prognosis of colorectal carcinomas.
出处 《西南国防医药》 CAS 2010年第5期492-494,共3页 Medical Journal of National Defending Forces in Southwest China
关键词 结直肠癌 EphB-2受体 HER-2 EGFR 诊断 预后 colorectal carcinoma EphB-2 receptor HER-2 EGFR diagnosis prognosis
  • 相关文献

参考文献3

二级参考文献102

  • 1康小伟.Ras蛋白与信号传导[J].生命科学,1996,8(2):24-26. 被引量:11
  • 2袁志忠,叶挺军,陈泳莲.脑胶质瘤表皮生长因子受体表达及其意义[J].中华病理学杂志,1996,25(6):369-370. 被引量:3
  • 3Ohtsu A.Chemotherapy for metastatic gastric cancer:past,present,and future.J Gastroenterol 2008; 43:256-264
  • 4Demetri GD,von Mehren M,Blanke CD,Van den Abbeele AD,Eisenberg B,Roberts PJ,Heinrich MC,Tuveson DA,Singer S,Janicek M,Fletcher JA,Silverman SG,Silberman SL,Capdeville R,Kiese B,Peng B,Dimitrijevic S,Druker BJ,Corless C,Fletcher CD,Joensuu H.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med 2002; 347:472-480
  • 5Blanke CD,Demetri GD,von Mehren M,Heinrich MC,Eisenberg B,Fletcher JA,Corless CL,Fletcher CD,Roberts PJ,Heinz D,Wehre E,Nikolova Z,Joensuu H.Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.J Clin Oncol 2008; 26:620-625
  • 6Casali PG,Jost L,Reichardt P,Schlemmer M,Blay JY.Gastrointestinal stromal tumors:ESMO clinical recommendations for diagnosis,treatment and follow-up.Ann Oncol 2008; 19 Suppl 2:ii35-ii38
  • 7Demetri GD,van Oosterom AT,Garrett CR,Blackstein ME,Shah MH,Verweij J,McArthur G,Judson IR,Heinrich MC,Morgan JA,Desai J,Fletcher CD,George S,Bello CL,Huang X,Baum CM,Casali PG.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial.Lancet 2006; 368:1329-1338
  • 8Vanhoefer U,Tewes M,Rojo F,Dirsch O,Schleucher N,Rosen O,Tillner J,Kovar A,Braun AH,Trarbach T,Seeber S,Harstrick A,Baselga J.Phase Ⅰ study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.J Clin Oncol 2004; 22:175-184
  • 9Kim T.Technology evaluation:Matuzumab,Merck KGaA.Curr Opin Mol Ther 2004; 6:96-103
  • 10Dragovich T,McCoy S,Fenoglio-Preiser CM,Wang J,Benedetti JK,Baker AF,Hackett CB,Urba SG,Zaner KS,Blanke CD,Abbruzzese JL.Phase Ⅱ trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG 0127.J Clin Oncol 2006; 24:4922-4927

共引文献53

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部